EXAS
NASDAQ · Biotechnology
Exact Sciences Corp
$104.91
+0.99 (+0.95%)
Financial Highlights (FY 2026)
Revenue
3.28B
Net Income
-210,377,895
Gross Margin
69.7%
Profit Margin
-6.4%
Rev Growth
+15.9%
D/E Ratio
0.97
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 69.7% | 69.7% | 65.2% | 65.2% |
| Operating Margin | -6.3% | -5.7% | -19.8% | -16.2% |
| Profit Margin | -6.4% | -6.1% | -15.6% | -20.5% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 3.28B | 2.83B | 5.75B | 5.27B |
| Gross Profit | 2.29B | 1.97B | 3.75B | 3.43B |
| Operating Income | -208,587,497 | -161,946,814 | -1,140,404,105 | -853,966,878 |
| Net Income | -210,377,895 | -163,336,875 | -895,146,132 | -1,079,598,147 |
| Gross Margin | 69.7% | 69.7% | 65.2% | 65.2% |
| Operating Margin | -6.3% | -5.7% | -19.8% | -16.2% |
| Profit Margin | -6.4% | -6.1% | -15.6% | -20.5% |
| Rev Growth | +15.9% | +15.9% | -4.7% | +13.8% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 4.94B | 4.94B | 1.25B | 1.44B |
| Total Equity | 5.07B | 5.07B | 14.33B | 13.57B |
| D/E Ratio | 0.97 | 0.97 | 0.09 | 0.11 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -82,368,262 | -67,503,320 | -1,423,315,581 | -1,251,341,027 |
| Free Cash Flow | — | — | -873,819,141 | -1,059,999,929 |